25results about "Colony-stimulating factor" patented technology

The present invention provides a bifunctional molecule comprising an Fc mutant antibody linked to a cytokine, and the use of the bifunctional molecule in the manufacture of a therapeutic antibody drug. These Fc mutant monoclonal antibodies, monoclonal antibody / antigen complexes, or Fc fusion proteins can significantly reduce toxicity and side effects in vivo while maintaining the biological activity of the original antibody in vivo and in vivo.

This invention provides a side-chain coupled compound of a cell-binding molecule having a branched linker and an amanita toxin compound. [Solution] A side-chain conjugated compound of formula (I), TIFF2026097851000286.tif25170 In one embodiment, a side-chain conjugated compound is provided, in which T is a cell-binding agent / molecule, W is a C1-C18 extension unit, and D is an amanita toxin, or an isotope of a chemical element, or a pharmaceutically acceptable salt, hydrate, or hydrated salt; or a polymorphic crystal; or an optical isomer, racemate, diastereomer, or enantiomer thereof.

The invention relates to single chain polypeptides having IL-10 and CSF1 activities and to their use in therapy.

To provide a method for producing professional antigen-presenting cells, and to provide the professional antigen-presenting cells.SOLUTION: Provided are a method for producing professional antigen-presenting cells, including obtaining proliferative myeloid cells (pMC) by expressing c-MYC or the like in myeloid cells (MC) differentiated from pluripotent stem cells, and obtaining professional antigen-presenting cells (pAPC) by expressing GM-CSF and / or M-CSF in the pMC, and human professional antigen-presenting cells produced by the method.SELECTED DRAWING: None

A genetically-modified, immunodeficient mouse is provided along with methods of use, wherein the mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSFl), wherein each of the nucleotide sequences is operably linked to a promoter, and wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSFl, wherein the genetically-modified, immunodeficient mouse allows engraftment of human hematopoietic stem cells along with engraftment of human-patient derived tumor xenografts and / or human tumor cell lines to enable in vivo investigation of the interactions between the human immune system and human cancer.

The present application relates to immunomodulatory molecules comprising a first binding domain (e.g., an immunostimulatory cytokine, such as IL-2 or IL-12, or a variant thereof) that specifically recognizes a first target molecule (e.g., a receptor for an immunostimulatory cytokine) and a second binding domain (e.g., an agonist ligand, such as PD-L1 or PD-L2, or a variant thereof, or an agonist antigen-binding fragment, such as an anti-PD-1 agonist Fab, scFv, VHH, or full length antibody) that specifically recognizes a second target molecule (e.g., an inhibitory checkpoint molecule, such as PD-1), wherein the first binding domain, upon binding to the first target molecule, upregulates an immune response and the second binding domain, upon binding to the second target molecule, downregulates an immune response. Methods of making and using such immunomodulatory molecules are also provided.

Provided is a method for producing professional antigen-presenting cells, said method comprising allowing myeloid cells (MC), which are differentiated from pluripotent stem cells, to express c-MYC, etc. to thereby give proliferating myeloid cells (pMC) and allowing the pMC to express GM-CSF and / or M-CSF to thereby give professional antigen-presenting cells (pAPC). Also provided are human professional antigen-presenting cells produced by this method.

A method for producing professional antigen-presenting cells and professional antigen-presenting cells are provided. [Solution] We provide a method for producing professional antigen-presenting cells, which includes obtaining proliferative myeloid cells (pMCs) by expressing c-MYC or the like in myeloid cells (MCs) differentiated from pluripotent stem cells, and obtaining professional antigen-presenting cells (pAPCs) by expressing GM-CSF and / or M-CSF in the pMCs, as well as human professional antigen-presenting cells produced by this method.

Disclosed are single chain polypeptides exhibiting both Interleukin-10 (IL-10) and Colony-Stimulating Factor 1 (CSF1) activities. The polypeptides are engineered to selectively deliver the anti-inflammatory effects of IL-10 to myeloid cells that express the CSF1 receptor (CSF1R). In one embodiment, the polypeptide comprises a CSF1 monomer fused via a peptide linker to an IL-10 monomer. In another embodiment, the polypeptide comprises a single chain dimeric IL-10 fused to a CSF1 monomer. These fusion proteins provide targeted anti-inflammatory activity while reducing systemic effects on other immune cells. Pharmaceutical compositions containing these polypeptides and their use for treating inflammatory diseases, such as inflammatory bowel disease, are also provided.

This specification describes immunogenic compositions comprising tumor cells expressing a fusokine containing GM-CSF linked to IL-7 by a peptide linker. Also described are pharmaceutical compositions and methods for treating patients with glioblastoma using tumor cells expressing a fusokine containing GM-CSF linked to IL-7 by a peptide linker.

A method of identifying anti-tumor activity of a test substance is provided along with a genetically-modified, immunodeficient mouse and methods of use, wherein the genetically-modified, immunodeficient mouse enables in vivo investigation of the interactions between the human immune system and human cancer.

An immunoresponsive cell, such as a T-cell expressing(i) a second generation chimeric antigen receptor comprising:(a) a signalling region;(b) a co-stimulatory signalling region;(c) a transmembrane domain; and(d) a binding element that specifically interacts with a first epitope on a target antigen; and(ii) a chimeric costimulatory receptor comprising(e) a co-stimulatory signalling region which is different to that of (b);(f) a transmembrane domain; andg) a binding element that specifically interacts with a second epitope on a target antigen.This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.

In various embodiments, the present disclosure provides non-human animals comprising human immune cell transplantation and / or a functional human immune system. In various embodiments, the disclosure also provides methods of making the non-human animal. In various embodiments, the disclosure also provides methods of determining the immunogenicity of an antigen or an immunogenic fragment thereof or an antigen therapy and / or identifying an agent that modulates an immune response.

Genetically engineered progenitor cells and methods of using the same are disclosed herein. Genetically engineered cells differentiated from the genetically engineered progenitor cells of the present disclosure are also disclosed herein. Also disclosed herein is a method of treating a condition in a subject by administering the genetically engineered progenitor cells of the present disclosure or the genetically engineered cells differentiated from the genetically engineered progenitor cells.

Compositions and methods for modifying granulocyte-macrophage colony-stimulating factor (GM-CSF) as described. Non-naturally occurring cell engineered for production of GM-CSF with an altered glycosylation pattern comprising an expression vector having the CSF2 gene, and one or more knockout genes selected from the group consisting of MGAT5, ST3GAL3, ST3GAL4, ST3GAL6, B3GNT2, SPPL3, MGAT4A, and MGAT4B. In some embodiments, the cell additionally comprises a knock-in gene consisting of HST6GAL1.

The present invention provides: an oncolytic virus such as a conditionally replicating adenovirus carrying the CXCL10 gene; the oncolytic virus additionally carrying the IL-2 gene and / or the GM-CSF gene on the same viral genome; a combination of the oncolytic virus and a separate oncolytic virus carrying the IL-2 gene and / or the GM-CSF gene; and a cancer treatment agent comprising any of the aforementioned oncolytic viruses or a combination thereof as an active ingredient.

The disclosure provides, in various embodiments, non-human animals that comprise a human immune cell engraftment and / or functional human immune system. The disclosure also provides, in various embodiments, methods of generating said non-human animals. The disclosure also provides, in various embodiments, methods of determining immunogenicity of antigens or an immunogenic fragment thereof or antigenic therapies and / or identifying agents that modulate immune response.

The present invention relates to single chain polypeptides having IL-10 activity and CSF1 activity and their use in therapy.

Provided are a recombinant oncolytic virus and a use thereof. The recombinant oncolytic virus includes an M protein and a cytokine encoded by an exogenous gene, wherein the M protein includes the following site mutations compared to an amino acid sequence as shown in SEQ ID NO 1: mutating of methionine at position 51 into arginine (M51R); mutating of valine at position 221 into phenylalanine (V221F); and mutating of serine at position 226 into arginine (S226R). The recombinant oncolytic viruses of the present application all have better infective ability and killing ability in vitro to abnormally proliferative (tumor) LLC cell, 4T1 cell, MC38 cell and Hela cell, and are not easy to eliminate in LLC cell, 4T1 cell, MC38 cell and Hela cell, greatly reducing the infective ability of the recombinant oncolytic viruses to normal cells.

Conjugates of a CSF-1 moiety and one or more water soluble polymers are provided. Typically, the water soluble polymer is a poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising conjugates, methods of making conjugates, methods of using the conjugates or compositions in therapeutic treatments, methods of administering conjugates or compositions comprising the conjugates to a patient, and kits comprising conjugates.

The invention relates to the technical field of biological medicine, and discloses an engineering bacterium carrier as well as a preparation method and application thereof. The costimulatory factor and the histidine tag are expressed on the surface of the outer membrane of the escherichia coli, and the histidine tag is connected with the quantum dots. According to the engineering bacterium vector provided by the invention, costimulatory factors and histidine tags are expressed on the surface of an outer membrane of escherichia coli through gene modification, and quantum dots are further modified through the histidine tags, so that triple synergistic anti-tumor effects are realized: (1) precise targeting: the natural tumor tropism of escherichia coli is utilized; actively colonizing in an anoxic tumor core area; (2) immune activation: directly activating T cells in a tumor microenvironment by a surface costimulatory factor to overcome immunosuppression; (3) light-operated treatment: the quantum dots enhance generation of bacterial endogenous NO under laser irradiation, synchronously kill tumor cells and promote polarization of macrophage M1; the obtained engineering bacterium carrier has the functions of targeted delivery, immune regulation and controllable treatment.

An immunoresponsive cell, such as a T-cell expressinga second generation chimeric antigen receptor comprising:(a) a signalling region;(b) a co-stimulatory signalling region;(c) a transmembrane domain; and(d) a binding element that specifically interacts with a first epitope on a target antigen; anda chimeric costimulatory receptor comprising(e) a co-stimulatory signalling region which is different to that of (b);(f) a transmembrane domain; andg) a binding element that specifically interacts with a second epitope on a target antigen.This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.

An object of the present invention is to provide a mesenchymal stem cell having excellent cell adhesiveness and capable of obtaining a sufficient cell proliferation rate without requiring a serum medium.SOLUTION: The present invention relates to a mesenchymal stem cell in which a production amount of a granulocyte colony-stimulating factor (G-CSF) is enhanced. The present invention also includes a mesenchymal stem cell in which a production amount of at least one selected from the group consisting of eotaxin, fractalkine, GRO, MCP-3, and VEGF is enhanced.SELECTED DRAWING: None

The purpose of the present invention is to provide mesenchymal stem cells that have exceptional cell adhesiveness, do not require serum medium, and have an adequate cell proliferation rate.　The present invention is mesenchymal stem cells characterized in that the amount of granulocyte colony stimulating factor (G-CSF) produced is enhanced. The present invention also includes mesenchymal stem cells characterized in that the amount of at least one selected from the group consisting of eotaxin, fractalkine, GRO, MCP-3, and VEGF produced is enhanced.